[1]
|
Bäckhed, F., Ley, R.E., Sonnenburg, J.L., Peterson, D.A. and Gordon, J.I. (2005) Host-Bacterial Mutualism in the Human Intestine. Science, 307, 1915-1920. https://doi.org/10.1126/science.1104816
|
[2]
|
Blanton, L.V., Char-bonneau, M.R., Salih, T., et al. (2016) Gut Bacteria That Prevent Growth Impairments Transmitted by Microbiota from Malnourished Children. Science, 351, 854. https://doi.org/10.1126/science.aad3311
|
[3]
|
Dao, M.C., Everard, A., Aron-Wisnewsky, J., et al. (2016) Akkermansia muciniphila and Improved Metabolic Health during a Dietary Inter-vention in Obesity: Relationship with Gut Microbiome Richness and Ecology. Gut, 65, 426-436.
https://doi.org/10.1136/gutjnl-2014-308778
|
[4]
|
Plovier, H, Everard, A., Druart, C., et al. (2017) A Purified Membrane Protein from Akkermansia muciniphila or the Pasteurized Bacterium Improves Metabolism in Obese and Diabetic Mice. Nature Medicine, 23, 107-113.
https://doi.org/10.1038/nm.4236
|
[5]
|
国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版) [J]. 中华外科杂志, 2022, 60(4): 273-309.
|
[6]
|
Gupta, H., Youn, G.S., Shin, M.J. and Suk, K.T. (2019) Role of Gut Microbiota in Hepatocarcinogenesis. Microorganisms, 7, Article No. 121. https://doi.org/10.3390/microorganisms7050121
|
[7]
|
Zhang, L., Wu, Y.N., Chen, T., et al. (2019) Relationship between Intestinal Microbial Dysbiosis and Primary Liver Cancer. Hepatobiliary & Pancreatic Diseases International, 18, 149-157. https://doi.org/10.1016/j.hbpd.2019.01.002
|
[8]
|
Huang, H., Ren, Z., Gao, X., et al. (2020) Integrated Analysis of Microbiome and Host Transcriptome Reveals Correlations between Gut Microbiota and Clinical Outcomes in HBV-Related Hepatocellular Carcinoma. Genome Medicine, 12, Article No. 102. https://doi.org/10.1186/s13073-020-00796-5
|
[9]
|
Temraz, S., Nassar, F., Kreidieh, F., et al. (2021) Hepatocellular Carcinoma Immunotherapy and the Potential Influence of Gut Microbiome. International Journal of Molecular Sciences, 22, Article No. 7800.
https://doi.org/10.3390/ijms22157800
|
[10]
|
Hu, C., Xu, B., Wang, X., et al. (2022) Gut Microbiota-Derived Short-Chain Fatty Acids Regulate Group 3 Innate Lymphoid Cells in HCC. Hepatology, 1-17. https://doi.org/10.1002/hep.32449
|
[11]
|
Bajaj, J.S., Fagan, A., Sikaroodi, M., et al. (2019) Alterations in Skin Microbiomes of Patients with Cirrhosis. Clinical Gastroenterology and Hepatology, 17, 2581-2591. https://doi.org/10.1016/j.cgh.2019.03.028
|
[12]
|
Schwabe, R.F. and Greten, T.F. (2020) Gut Microbiome in HCC-Mechanisms, Diagnosis and Therapy. Journal of Hepatology, 72, 230-238. https://doi.org/10.1016/j.jhep.2019.08.016
|
[13]
|
Zhang, N., Gou, Y., Liang, S., et al. (2021) Dysbiosis of Gut Microbiota Promotes Hepatocellular Carcinoma Progression by Regulating the Immune Response. Journal of Immu-nology Research, 2021, Article ID: 4973589.
https://doi.org/10.1155/2021/4973589
|
[14]
|
Chattopadhyay, I., Gundamaraju, R., Jha, N.K., et al. (2022) Interplay between Dysbiosis of Gut Microbiome, Lipid Metabolism, and Tumorigenesis: Can Gut Dysbiosis Stand as a Prognostic Marker in Cancer? Disease Markers, 2022, Article ID: 2941248. https://doi.org/10.1155/2022/2941248
|
[15]
|
Jia, B. (2019) Commentary: Gut Microbiome-Mediated Bile Acid Metabolism Regulates Liver Cancer via NKT Cells. Frontiers in Immunology, 10, Article 282. https://doi.org/10.3389/fimmu.2019.00282
|
[16]
|
Ma, C., Han, M., Heinrich, B., et al. (2018) Gut Microbiome-Mediated Bile Acid Metabolism Regulates Liver Cancer via NKT Cells. Science, 360, eaan5931. https://doi.org/10.1126/science.aan5931
|
[17]
|
Shen, R., Ke, L., Li, Q., et al. (2022) Abnormal Bile Ac-id-Microbiota Crosstalk Promotes the Development of Hepatocellular Carcinoma. Hepatology International, 16, 396-411. https://doi.org/10.1007/s12072-022-10299-7
|
[18]
|
Zhang, J., Yang, S., Wang, J., et al. (2021) Integrated LC-MS Metabolomics with Dual Derivatization for Quantification of FFAs in Fecal Samples of Hepatocellular Carcinoma Patients. Journal of Lipid Research, 62, Article ID: 100143. https://doi.org/10.1016/j.jlr.2021.100143
|
[19]
|
Kang, J., Li, C., Gao, X., et al. (2021) Metformin Inhibits Tumor Growth and Affects Intestinal Flora in Diabetic Tumor-Bearing Mice. European Journal of Pharmacology, 912, Article ID: 174605.
https://doi.org/10.1016/j.ejphar.2021.174605
|
[20]
|
McBrearty, N., Arzumanyan, A., Bichenkov, E., et al. (2021) Short Chain Fatty Acids Delay the Development of Hepatocellular Carcinoma in HBx Transgenic Mice. Neoplasia, 23, 529-538. https://doi.org/10.1016/j.neo.2021.04.004
|
[21]
|
Figueroa, L., Xiong, Y., Song, C., et al. (2012) The Asp299Gly Polymorphism Alters TLR4 Signaling by Interfering with Recruitment of MyD88 and TRIF. The Journal of Immunology, 188, 4506-4515.
https://doi.org/10.4049/jimmunol.1200202
|
[22]
|
Du, M., Yuan, L., Tan, X., et al. (2017) The LPS-Inducible lncRNA Mirt2 Is a Negative Regulator of Inflammation. Nature Communications, 8, Article No. 2049. https://doi.org/10.1038/s41467-017-02229-1
|
[23]
|
Li, N., Xu, H., Ou, Y., et al. (2019) LPS-Induced CXCR7 Ex-pression Promotes Gastric Cancer Proliferation and Migration via the TLR4/MD-2 Pathway. Diagnostic Pathology, 14, Article No. 3.
https://doi.org/10.1186/s13000-019-0780-x
|
[24]
|
Zahran, A.M., Zahran, Z.A.M., El-Badawy, O., et al. (2019) Prognostic Impact of Toll-Like Receptors 2 and 4 Expression on Monocytes in Egyptian Patients with Hepatocellular Carcinoma. Immunologic Research, 67, 157-165.
https://doi.org/10.1007/s12026-019-09075-x
|
[25]
|
Yun, J., Yu, G., Hu, P., et al. (2020) PD-1 Expression Is Ele-vated in Monocytes from Hepatocellular Carcinoma Patients and Contributes to CD8 T Cell Suppression. Immunologic Research, 68, 436-444.
https://doi.org/10.1007/s12026-020-09155-3
|
[26]
|
Elshaer, A.M., El-Kharashi, O.A., Hamam, G.G., et al. (2019) Involvement of TLR4/CXCL9/PREX-2 Pathway in the Development of Hepatocellular Carcinoma (HCC) and the Promising Role of Early Administration of Lactobacillus Plantarum in Wistar Rats. Tissue and Cell, 60, 38-47. https://doi.org/10.1002/cam4.3045
|
[27]
|
Zheng, R., Wang, G., Pang, Z., et al. (2020) Liver Cirrhosis Contributes to the Disorder of Gut Microbiota in Patients with Hepatocellular Carcinoma. Cancer Medicine, 9, 4232-4250. https://doi.org/10.1002/cam4.3045
|
[28]
|
Piñero, F., Vazquez, M., Baré, P., et al. (2019) A Different Gut Microbiome Linked to Inflammation Found in Cirrhotic Patients with and without Hepatocellular Carcinoma. Annals of Hepatology, 18, 480-487.
https://doi.org/10.1016/j.jhep.2019.08.016
|
[29]
|
Wu, R., Mei, X., Ye, Y., et al. (2019) Zn(II)-Curcumin Solid Dispersion Impairs Hepatocellular Carcinoma Growth and Enhances Chemotherapy by Modulating Gut Microbiota-Mediated Zinc Homeostasis. Pharmacological Research, 150, Article ID: 104454. https://doi.org/10.1016/j.phrs.2019.104454
|
[30]
|
Routy, B., Le Chatelier, E., Derosa, L., et al. (2018) Gut Microbiome Influences Efficacy of PD-1-Based Immunotherapy against Epithelial Tumors. Science, 359, 91-97. https://doi.org/10.1126/science.aan3706
|
[31]
|
Ervin, S.M., Hanley, R.P., Lim, L., et al. (2019) Targeting Regorafenib-Induced Toxicity through Inhibition of Gut Microbial β-Glucuronidases. ACS Chemical Biology, 14, 2737-2744. https://doi.org/10.1021/acschembio.9b00663
|
[32]
|
Wass Thilakarathna, W.P.D., Vasantha Rupasinghe, H.P. and Ridgway, N.D. (2021) Mechanisms by Which Probiotic Bacteria Attenuate the Risk of Hepatocellular Carci-noma. International Journal of Molecular Sciences, 22, Article No. 2606. https://doi.org/10.3390/ijms22052606
|
[33]
|
Darvesh, A.S. and Bishayee, A. (2013) Chemopreventive and Thera-peutic Potential of Tea Polyphenols in Hepatocellular Cancer. Nutrition and Cancer, 65, 329-344. https://doi.org/10.1080/01635581.2013.767367
|
[34]
|
Cheung, K.S., Lam, L.K., Seto, W.K. and Leung, W.K. (2021) Use of Antibiotics during Immune Checkpoint Inhibitor Treatment Is Associated with Lower Survival in Hepatocellular Carcinoma. Liver Cancer, 10, 606-614.
https://doi.org/10.1159/000518090
|
[35]
|
Pomej, K., Balcar, L., Scheiner, B., et al. (2021) Antibiotic Therapy Is Associated with Worse Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib. Journal of Hepa-tocellular Carcinoma, 8, 1485-1493.
https://doi.org/10.2147/JHC.S317957
|